Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Serine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.53 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.53 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.48 |
| ▸ | GSR | P00390 | 2/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Serine SCHEMBL7925103 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2SLC1A1SLC1A3 | |
| Serine SCHEMBL3052911 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2SLC1A1SLC1A3 | |
| Serine SCHEMBL1064691 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2SLC1A1SLC1A3 | |
| Serine SCHEMBL5271398 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2SLC1A1SLC1A3 | |
| Serine SCHEMBL12500456 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2SLC1A1SLC1A3 | |
| (D)-Serine SCHEMBL3502795 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2SLC1A1SLC1A3 | |
| Serine SCHEMBL7925095 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2SLC1A1SLC1A3 | |
| Serine SCHEMBL8651361 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2SLC1A1SLC1A3 | |
| Serine SCHEMBL20511092 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2SLC1A1SLC1A3 | |
| Serine SCHEMBL3821536 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2SLC1A1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283124-B1 | BIOCONJUGATES AND USES THEREOF | SYMIC HOLDINGS USA INC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11530420-B2 | Nucleic acid construct | Autolus Limited (GB) | 2022-12-20 | — | — | US | disclosed |
| EP-3288968-B1 | NUCLEIC ACID CONSTRUCT | UCL BUSINESS LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| US-20200078469-A1 | HEPARIN-PEPTIDE BIOCONJUGATES AND USES THEREOF | Symic OA ApS (DK) | 2020-03-12 | — | — | US | disclosed |
| EP-3288969-B1 | NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR | UCL BUSINESS LTD (GB) | 2020-02-19 | — | — | EP | disclosed |
| EP-3288970-B1 | NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR | UCL BUSINESS LTD (GB) | 2020-02-19 | — | — | EP | disclosed |
| US-20180111993-A1 | NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR | Autolus Limited (GB) | 2018-04-26 | — | — | US | disclosed |
| US-20180105573-A1 | NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR | Autolus Limited (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180104321-A1 | NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR | Autolus Limited (GB) | 2018-04-19 | — | — | US | disclosed |
| US-20180100163-A1 | NUCLEIC ACID CONSTRUCT | Autolus Limited (GB) | 2018-04-12 | — | — | US | disclosed |
| EP-3283124-A1 | BIOCONJUGATES AND USES THEREOF | Symic IP, LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170112941-A1 | VE-CADHERIN BINDING BIOCONJUGATE | SYMIC IP, LLC | 2017-04-27 | — | — | US | disclosed |
| WO-2017066349-A1 | VE-CADHERIN BINDING BIOCONJUGATE | SYMIC IP, LLC (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20160331841-A1 | BIOCONJUGATES AND USES THEREOF | SYMIC IP, LLC | 2016-11-17 | — | — | US | disclosed |
| WO-2016174407-A1 | NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR | UCL BUSINESS PLC (GB) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016174408-A1 | NUCLEIC ACID CONSTRUCT | UCL BUSINESS PLC (GB) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016174405-A1 | NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR | UCL BUSINESS PLC (GB) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016174406-A1 | NUCLEIC ACID CONSTRUCT FOR EXPRESSING MORE THAN ONE CHIMERIC ANTIGEN RECEPTOR | UCL BUSINESS PLC (GB) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016168743-A1 | BIOCONJUGATES AND USES THEREOF | SYMIC IP, LLC (US) | 2016-10-20 | — | — | WO | disclosed |
| CN-102481341-A | Proproteins and methods of use thereof | CYTOMX THERAPEUTICS LLC | 2012-05-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078469-A1 | HEPARIN-PEPTIDE BIOCONJUGATES AND USES THEREOF | CD44, VCAM1, ICAM1 | GLRA1 2296/4885SLC6A9 2568/4885OR51E2 1574/4885 |
| US-20160331841-A1 | BIOCONJUGATES AND USES THEREOF | CD44, VCAM1, ICAM1 | GLRA1 2242/4885SLC6A9 2310/4885OR51E2 1369/4885 |
| US-20170112941-A1 | VE-CADHERIN BINDING BIOCONJUGATE | EPCAM, CDH1, VCAM1 | GLRA1 2983/4885SLC6A9 3033/4885OR51E2 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.